Systemic and presystemic conversion of carbamazepine to carbamazepine-10,11-epoxide during long term treatment

Journal of Epilepsy and Clinical Neurophysiology

Volumn 12, Issue 1, 2006, Pages 13-16

  Fagiolino, Pietro ^a,b   Vázquez, Marta ^a,b   Olano, Ivette ^a,b   Delfino, Aurora ^a,c  

^a Chemistry School   (Uruguay)

^b University Hospital: Dr Manuel Quintela   (Uruguay)

^c Children's Hospital: Pereira Rossell ^*

Author keywords

Autoinduction; Bioavailability; Carbamazepine; Presystemic biotransformation

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CYTOCHROME P450 3A4; MULTIDRUG RESISTANCE PROTEIN 2;

ADOLESCENT; ADULT; ARTICLE; BIOTRANSFORMATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EPILEPSY; FEMALE; GRAPEFRUIT JUICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LONG TERM CARE; MALE; MONOTHERAPY; PROTEIN INDUCTION;

EID: 34547891555     PISSN: 16762649     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1676-26492006000100004     Document Type: Article

References (10)

1. Spina E, Pisani F, Perucca E. Clinical significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31(3):198-214.
2. Pelkonen O, Myllynen P, Taavitsainen P, Boobis AR, Watts P, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo A, Corcos L, Goldfarb PS, Lewis DF. Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 2001; 31(6):321-43.
3. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Dose - dependent metabolism of Carbamazepine in humans. Epilepsy Res 1996; 24(3):163-72.
4. Battino D, Croci D, Rossini A, Messina S, Mamoli D, Perucca E. Serum carbamazepine concentrations in elderly patients: a casematched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia 2003; 44(7):923-9.
5. Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther 1998; 64(3):286-8.
6. Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, Dazert P, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer HK, Siegmund W. Carbamazepine regulates intestinal Pglycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 2004; 76(3):192-200.
7. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome P450 3A substrates. Clin Pharmacokinet 2003; 42(11):969-84.
8. Olano I., Vázquez M., Fagiolino P., Chronopharmacokinetics of Carbamazepine and its metabolite 10,11-epoxide. J Pharm Clin 1998; 17(3):153-6.
9. Spina E, Martines C, Fazio A, Trio R, Pisani F, Tomson T. Effect of Phenobarbital on the pharmacokinetics of Carbamazepine-10,11-epoxide, an active metabolite of Carbamazepine. Ther Drug Monit 1991; 13(2):109-12.
10. Amidon GL, Lennernas H, Shah VP, Crison JR. A Theoretical Basis For a Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability. Pharm Res 1995; 12:413-20.